Skip to main content
SpringerLink
Log in

Lungenkarzinom

Non-small cell lung cancer

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Das Lungenkarzinom ist weltweit die am häufigsten zum Tode führende Krebserkrankung. Da Frühsymptome des Tumors extrem selten sind, liegt bei sich symptomatisch vorstellenden Patienten meist ein fortgeschrittenes Tumorstadium vor. Anhand einer strukturierten Diagnostik wird der Tumor klassifiziert und einer entsprechenden Therapie zugeführt. Bei lokoregional begrenztem nichtkleinzelligem Bronchialkarzinom (NSCLC) ist die chirurgische Therapie indiziert. Nach kompletter Tumorresektion im Stadium (IB)–II sowie im inzidentellen Stadium IIIA sollte eine platinbasierte adjuvante Kombinationschemotherapie empfohlen werden. Eine definitive Radiochemotherapie ist bei prognostisch inoperablem, lokal fortgeschrittenem, nichtkleinzelligem Lungenkarzinom Standardtherapie. Die Rolle der „targeted“-Therapie wird intensiv untersucht.

Abstract

Lung cancer is the most frequent form of cancer leading to death worldwide. Since early symptoms of the tumor are extremely rare, advanced tumor stage can as a rule be assumed when a patient presents with symptoms. The tumor is classified on the basis of structured diagnostic findings, followed by the appropriate treatment. Surgery is indicated for locoregionally circumscribed non-small cell lung cancer (NSCLC). After complete tumor resection in stage IB, IIA and IIIA (incidental), adjuvant platinum-based combination chemotherapy is recommended. Definitive radiochemotherapy is the standard treatment for patients with locally advanced non-small cell lung cancer deemed inoperable based on prognosis. The role of targeted therapy is currently the subject of intensive investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adamietz IA (2010) NSCLC: Palliative procedures in stage IV. Radiotherapy. In: Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds) Controversies in the treatment of lung cancer. Karger, Basel, pp 164–172

  2. Albain KS, Jablons D, Werner-Wasik A et al (2006) Stage II non-small-cell lung cancer. Tailored therapies for a complex disease. Educational Book. American Society of Clinical Oncology, Alexandria, 453–462

  3. Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379–386

    Article  CAS  PubMed  Google Scholar 

  4. Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360

    Article  PubMed  Google Scholar 

  5. Berlin NI, Buncher CR, Fontana RS et al (1984) The National Cancer Institute cooperative early lung cancer detection program. Results of the initial screen (prevalence). Early lung cancer detection: Introduction. Am Rev Respir Dis 130:545–549

    CAS  PubMed  Google Scholar 

  6. Bollmann A, Blankenburg T, Haerting J et al (2004) Survival of patients in clinical stages I–IIIb of non-small-cell lung cancer treated with radiation therapy alone. Results of a population-based study in Southern Saxony-Anhalt. Strahlenther Onkol 180:488–496

    Article  PubMed  Google Scholar 

  7. Bonomi PD. (2010) Implications of key trials in advanced nonsmall cell lung cancer. Cancer 16:1155–1164

    Article  Google Scholar 

  8. Curran WJ, Scott CB, Langer CJ et al (2003) Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410 (abstr #621). J Clin Oncol [Suppl 1] 22:621

  9. Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247–253

    Article  PubMed  Google Scholar 

  10. Eberhardt W (2003) Induction therapy before surgery in stage III non-small-cell lung cancer. IASLC Brugges consensus. Lung Cancer [Suppl 1] 42:9–14

  11. Eberhardt W, Thomas M, Stuschke M et al (2006) Multimodale Behandlung des operablen lokal fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Onkologe 12:746–752

    Article  Google Scholar 

  12. Fischer B, Lassen U, Mortensen J et al (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32–39

    Article  CAS  PubMed  Google Scholar 

  13. Fischer BM, Eberhardt W, Buhl R et al (2006) Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. Onkologe 12:769–779

    Article  Google Scholar 

  14. Fleckenstein J, Appold S, Rübe C (2006) Palliative Radiotherapie beim nichtkleinzelligen Lungenkarzinom. Onkologe 12:780–785

    Article  Google Scholar 

  15. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95–01 study. J Clin Oncol 23:5910–5917

    Article  CAS  PubMed  Google Scholar 

  16. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    CAS  PubMed  Google Scholar 

  17. Hammond EC, Selikoff IJ, Seidman H (1979) Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 330:473–490

    Article  CAS  PubMed  Google Scholar 

  18. Herth FJF (2005) Diagnostische Bronchoskopie. Pneumologe 2:83–92

    Article  Google Scholar 

  19. Herth FJF, Dienemann H (2006) Diagnostik und Stadieneinteilung beim Lungenkarzinom. Onkologe 12:719–727

    Article  Google Scholar 

  20. Hoffmann H, Dienemann H, Passlick B (2006) Chirurgische Therapie des nichtkleinzelligen Lungenkarzinoms. Stadium I/II. Onkologe 12:728–736

    Article  Google Scholar 

  21. Huber RM, Reck M (2006) Supportive Therapie des nichtkleinzelligen Lungenkarzinoms. Onkologe 12:786–791

    Article  Google Scholar 

  22. Lahm H, Fischer JR (2003) Molekulargenetische Aspekte. In: Drings P, Dienemann H, Wannenmacher M (Hrsg) Management des Lungenkarzinoms. Springer, Berlin Heidelberg New York, S 21–35

  23. Lieven H von, Burkhardt E (2001) Postoperative radiotherapy of NSCLC – outcome after 3-D treatment planning. Strahlenther Onkol 177:302–306

    Article  Google Scholar 

  24. Meerbeeck JP van, Kramer G, Van Schil PE et al (2005) EORTC-Lung Cancer Group. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol [Suppl 1] 23:7015

  25. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  26. Niederle N, Schlag PM (2006) Nichtkleinzelliges Lungenkarzinom. Diagnostik und stadiengerechte Therapie. Onkologe 12:717–718

    Article  Google Scholar 

  27. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617–4625

    Article  Google Scholar 

  28. NSCLC Meta-Analyses Collaborative Group (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375:1267–1277

    Article  Google Scholar 

  29. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531

    Article  CAS  PubMed  Google Scholar 

  30. Reck M, Deppermann KM, Gatzemeier U et al (2006) Nichtkleinzelliges Lungenkarzinom. Palliative Chemotherapie im Stadium IV und bei Patienten mit Komorbidität. Onkologe 12:761–768

    Article  Google Scholar 

  31. Robinson L, Wagner H, Ruckdeschel J (2003) Treatment of stage III A non-small cell lung cancer. Chest 123:202–220

    Article  Google Scholar 

  32. Siegel BA, Dehdashti F (2005) Oncologic PET/CT: current status and controversies. Eur Radiol 15:127–132

    Article  Google Scholar 

  33. Spiro SG, Porter JC (2002) Lung cancer – where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166:1166–1196

    Article  PubMed  Google Scholar 

  34. Strauss GM, Herndon JE 2nd, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043–5051

    Article  CAS  PubMed  Google Scholar 

  35. Stuschke M, Huber RM, Flentje M et al (2006) Nichtkleinzelliges Lungenkarzinom im Stadium III. Onkologe 12:753–760

    Article  Google Scholar 

  36. Thomas M, Macha HN, Ukena D et al (2004) Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J Clin Oncol [Suppl] 22:7004

    Google Scholar 

  37. Thomas M, Dienemann H, Branscheid D et al (2006) Neoadjuvante/adjuvante Therapie in den frühen Stadien des nichtkleinzelligen Lungenkarzinoms. Onkologe 12:737–745

    Article  Google Scholar 

  38. US Environmental Protection Agency (USEPA) (1992) Respiratory health effects of passive smoking: lung cancer and other disorders. EPA/600/6–006 F. US Environmental Protection Agency, Washington

  39. Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589–2597

    Article  CAS  PubMed  Google Scholar 

  40. Wittekind C, Meyer HJ (2010) TNM Klassifikation maligner Tumoren. Wiley-Blackwell, New York, S 129–135

  41. Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:87–98

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Radioonkologie, Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Deutschland

    I.A. Adamietz

  2. Medizinische Klinik III, Klinikum Leverkusen, Leverkusen, Deutschland

    N. Niederle

Authors
  1. I.A. Adamietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I.A. Adamietz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adamietz, I., Niederle, N. Lungenkarzinom. Onkologe 16, 615–628 (2010). https://doi.org/10.1007/s00761-010-1853-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-010-1853-3

Schlüsselwörter

Keywords

Search

Navigation